Electrocardiographic Features of Sarcomere Mutation Carriers With and Without Clinically Overt Hypertrophic Cardiomyopathy

Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
The American journal of cardiology (Impact Factor: 3.43). 09/2011; 108(11):1606-13. DOI: 10.1016/j.amjcard.2011.07.019
Source: PubMed

ABSTRACT In hypertrophic cardiomyopathy (HC), electrocardiographic (ECG) changes have been postulated to be an early marker of disease, detectable in sarcomere mutation carriers when left ventricular (LV) wall thickness is still normal. However, the ECG features of mutation carriers have not been fully characterized. Therefore, we systematically analyzed ECGs in a genotyped HC population to characterize ECG findings in mutation carriers (G+) with and without echocardiographic LV hypertrophy (LVH), and to evaluate the accuracy of ECG findings to differentiate at-risk mutation carriers from genetically unaffected relatives during family screening. The ECG and echocardiographic findings were analyzed from 213 genotyped subjects (76 G+/LVH-, 57 G+/LVH+ overt HC, 80 genetically unaffected controls). Cardiac magnetic resonance imaging was available on a subset. Q waves and repolarization abnormalities (QST) were highly specific (98% specificity) markers for LVH- mutation carriers, present in 25% of G+/LVH- subjects, and 3% of controls (p <0.001). QST ECG abnormalities remained independently predictive of carrying a sarcomere mutation after adjusting for age and impaired relaxation, another distinguishing feature of G+/LVH- subjects (odds ratio 8.4, p = 0.007). Myocardial scar or perfusion abnormalities were not detected on cardiac magnetic resonance imaging in G+/LVH- subjects, irrespective of the ECG features. In overt HC, 75% had Q waves and/or repolarization changes, but <25% demonstrated common isolated voltage criteria for LVH. In conclusion, Q waves and repolarization abnormalities are the most discriminating ECG features of sarcomere mutation carriers with and without LVH. However, owing to the limited sensitivity of ECG and echocardiographic screening, genetic testing is required to definitively identify at-risk family members.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular hypertrophy (LVH) is associated with increased risk of sudden cardiac arrest (SCA); whether LVH diagnosed by 12-lead ECG versus echocardiogram conveys identical or distinct risk information has not been previously evaluated. To compare the association between ECG versus echocardiographic LVH and SCA in the community. In a large, prospective population-based study (Oregon SUDS; population approximately one million), cases of SCA were compared to controls recruited from the same geographical area. The association between LVH and SCA was evaluated, specifically comparing LVH diagnosed by ECG versus echocardiogram. Cases (n=132; 66.9 ± 13.5 years; 58.3% male), compared to controls (n= 211; 66.2 ± 12 years; 59.2% male) were more likely to have both ECG LVH (12.1% vs. 5.7%; p=0.03) and echocardiographic LVH (35.0% vs. 15.5%; p<0.001). However, there was poor agreement between the tests (kappa statistic = 0.128). A large subgroup of patients with ECG LVH (57.1%) did not have echocardiographic LVH; conversely 83.6% of patients with echocardiographic LVH did not have ECG LVH. In multivariate analysis, ECG LVH was significantly associated with SCA (OR 2.5; 95% CI 1.1-6.0; p=0.04). When echocardiographic LVH was added to the model, this association was only mildly attenuated (OR 2.4; 95% CI 1.0-6.0; p=0.05) and echocardiographic LVH was also independently associated with SCA (OR 2.7; 95% CI 1.5-4.9; p=0.001). ECG and echocardiographic LVH may convey distinct risk information in patients with SCA, reflecting electrical vs. anatomic remodeling. These findings have potential implications for SCA mechanisms and risk stratification.
    Heart rhythm: the official journal of the Heart Rhythm Society 03/2014; 11(6). DOI:10.1016/j.hrthm.2014.03.023 · 4.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: -Mutations in genes coding for sarcomeric proteins cause hypertrophic cardiomyopathy (HCM). Subtle abnormalities of the myocardium may be present in mutation carriers without hypertrophy (G+LVH-) but are difficult to quantify. Fractal analysis has been used to define trabeculae in LV noncompaction and to identify normal racial variations. We hypothesized that trabeculae measured by fractal analysis of cardiovascular magnetic resonance (CMR) images are abnormal in G+LVH- patients providing a preclinical marker of disease in HCM. -CMR was performed on 40 G+LVH- patients (33±15yrs, 38% men), 67 patients with a clinical diagnosis of HCM (53±15yrs, 76% men; 31 with a pathogenic mutation (G+LVH+)) and 69 matched healthy volunteers (44±15yrs, 57% men). Trabeculae were quantified by fractal analysis of cine slices to calculate the fractal dimension (FD) - a unitless index of endocardial complexity calculated from endocardial contours after segmentation. In G+LVH- patients apical LV trabeculation was increased compared to controls (maximal apical FD, 1.249±0.07 vs 1.199±0.05, P=0.001). In G+LVH+ and G-LVH+ cohorts, maximal apical FD was greater than in controls (P<0.0001) irrespective of gene status (G+LVH+: 1.370±0.08; G-LVH+: 1.380±0.09). Compared to controls, G+LVH- patients also had a higher frequency of clefts (28 vs 8%, P=0.02), longer anterior mitral valve leaflets (23.5±3.0 vs 19.7±3.1mm, P<0.0001), greater septal systolic wall thickness (12.6±3.2 vs 11.2±2.1mm, P=0.03), higher ejection fraction (71±4 vs 69±4 %, P=0.03) and smaller end-systolic volumes (38±9 vs 43±12mls, P=0.03). -Increased myocardial trabecular complexity is one of several preclinical abnormalities in HCM sarcomere gene mutation carriers without LVH.
    Circulation Cardiovascular Genetics 04/2014; 7(3). DOI:10.1161/CIRCGENETICS.113.000362 · 5.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mild hypertrophy but increased arrhythmic risk characterizes the stereotypic phenotype proposed for hypertrophic cardiomyopathy (HCM) caused by thin-filament mutations. However, whether such clinical profile is different from more prevalent thick-filament-associated disease is unresolved. This study aimed to assess clinical features and outcomes in a large cohort of patients with HCM associated with thin-filament mutations compared with thick-filament HCM. Adult HCM patients (age >18 years), 80 with thin-filament and 150 with thick-filament mutations, were followed for an average of 4.5 years. Compared with thick-filament HCM, patients with thin-filament mutations showed: 1) milder and atypically distributed left ventricular (LV) hypertrophy (maximal wall thickness 18 ± 5 mm vs. 24 ± 6 mm; p < 0.001) and less prevalent outflow tract obstruction (19% vs. 34%; p = 0.015); 2) higher rate of progression to New York Heart Association functional class III or IV (15% vs. 5%; p = 0.013); 3) higher prevalence of systolic dysfunction or restrictive LV filling at last evaluation (20% vs. 9%; p = 0.038); 4) 2.4-fold increase in prevalence of triphasic LV filling pattern (26% vs. 11%; p = 0.002); and 5) similar rates of malignant ventricular arrhythmias and sudden cardiac death (p = 0.593). In adult HCM patients, thin-filament mutations are associated with increased likelihood of advanced LV dysfunction and heart failure compared with thick-filament disease, whereas arrhythmic risk in both subsets is comparable. Triphasic LV filling is particularly common in thin-filament HCM, reflecting profound diastolic dysfunction. Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
    Journal of the American College of Cardiology 12/2014; 64(24):2589-600. DOI:10.1016/j.jacc.2014.09.059 · 15.34 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014